Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
Nothing solid landed today, just an early lab idea about safer blood thinners
-
The only item that came in was a preprint review, which means it has not been checked by other scientists yet.
-
It describes a new type of blood thinner that might lower clot risk with less bleeding, but that has not been tested in people with kidney disease.
-
There is nothing here to bring to your doctor yet, and no reason to change anything you are doing now.
Today was a quiet day for kidney research. One preprint review came through, looking at a new class of blood thinner designed to cut clotting without raising bleeding risk. Clotting and bleeding both matter a lot in kidney disease, so this is worth watching over time. But the work is early, unreviewed, and has not included kidney patients, so treat it as a idea being explored rather than news you can act on.
Effects of nandrolone decanoate on lean body mass and anemia in adults with chronic kidney disease: a systematic review and meta-analysis.
Researchers pooled the randomized trials of nandrolone decanoate, an injected anabolic steroid, in adults with chronic kidney disease. It targets two common problems: muscle and protein loss, and low red blood cell counts. They searched four medical databases up to February 18, 2026, and combined the trials they found. The measures were lean body mass, meaning muscle and organs rather than fat, and blood counts. Note what was not measured: whether people lived longer or kept kidney function.
Impact of nonsteroidal mineralocorticoid receptor antagonism on cardiorenal outcomes in diabetic kidney disease: a systematic review.
This review gathered randomized trials of finerenone and drugs like it in adults whose kidney disease comes from type 2 diabetes. These drugs block a hormone that makes the body hold onto salt, which raises blood pressure and strains the kidneys. The team searched five research databases through October 2024 and looked at both kidney and heart results, plus safety. A pooled review of randomized trials is the strongest kind of evidence, though this summary does not give the size of the benefit.
Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis
This review pooled many randomized trials in people who have both type 2 diabetes and chronic kidney disease. It compared three drug families against each other: GLP-1 drugs, SGLT2 inhibitors, and non-steroidal MRAs, which block a hormone that raises blood pressure and scars the kidney. It looked at heart and kidney outcomes and at side effects. Pooling randomized trials this way is the strongest kind of evidence for deciding which drug to reach for first.
Effect of a multimodal exercise program combined with inspiratory muscle training on cardiovascular recovery, functional capacity, and quality of life in CKD patients with Type 4 cardiorenal syndrome
This was a small trial of a mixed exercise program plus breathing-muscle training in people who have both kidney disease and heart failure, a combination doctors call type 4 cardiorenal syndrome. It measured heart recovery, how much physical activity people could manage, and their quality of life. The record came with no abstract, so the number of people, the length of the program, and the size of any benefit are not available here. Without those numbers, treat this as a promising direction rather than proof that the program works.
Hereditary thrombophilia due to a novel histidine-rich glycoprotein mutation leading to deferral of kidney transplantation: a case report.
A 42-year-old woman on dialysis kept getting blood clots in her dialysis access, the vein or graft used to connect her to the machine. Standard clotting tests looked normal, but low antithrombin and a high D-dimer, both blood markers of clotting trouble, led doctors to test her genes. They found a new mutation in the HRG gene that causes an inherited tendency to clot, and her kidney transplant was put off because of it. This is one patient, so it shows a possible link between this mutation and clotting, not proof that the mutation caused it.
Health, lifestyle and care barriers of night shift workers in Japan.
A nationwide online survey in Japan compared night shift workers with other workers on long-term illness, daily habits and trouble getting medical care. People reported their own health once, so this shows a link, not proof that shift work causes anything. The paper covers chronic disease in general and reports no kidney-specific finding. It is dropped from today's brief for that reason.
Retinal neurovascular signatures in response to 6-month yoga exercise in patients with Parkinson's Disease.
Seventeen people with Parkinson's disease, average age 71, did three one-hour yoga sessions a week for 24 weeks. Researchers measured blood flow and vessel density in the retina, the light-sensing layer at the back of the eye, before and after. Everyone did yoga, so there was no comparison group, and any change cannot be credited to the yoga. The study is about Parkinson's disease, not kidney disease, so it is out of scope here.
Association of GLP-1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 Diabetes.
Researchers compared GLP-1 drugs, the same family as semaglutide, against seven other diabetes medicines in Chinese adults with type 2 diabetes. They used regional health records from 2018 to 2024 and followed heart, kidney, and liver outcomes. This is a records study, so it can show a link but cannot prove the drug caused the difference. People given one drug often differ from people given another in ways the records do not capture.
SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network.
Fabry disease is a rare inherited illness that damages the kidneys and the heart, and there is very little research on which drugs help. This study used a large global network of patient records to see whether SGLT2 inhibitors, pills that protect kidneys in diabetes and heart failure, were linked to fewer heart events here too. It included adults with a kidney filtering rate (eGFR) of 20 or above. Because it draws on records rather than a trial, it shows a link and not proof of cause.
Genome-wide association study of estimated glomerular filtration rate using repeated measurements in the Taiwan Biobank
Researchers scanned the full genetic code of people in the Taiwan Biobank to find gene differences tied to kidney filtering rate (eGFR). Instead of one lab test per person, they used repeated tests over time, which gives a better picture of how kidney function changes. Gene studies like this show links and point to biology worth studying further. Nothing here changes treatment today.
Case Report: Advanced IgA nephropathy with psoriasis and a complex clinicopathologic course
This is a report on one person with advanced IgA nephropathy, a disease where the immune system damages the kidney's filters. The same person also had psoriasis, a skin disease, and their illness took a complicated turn. A single patient's story can show a possible link, not proof that one condition caused the other. It cannot tell you what will happen to anyone else.
Prognostic evaluation of boys with posterior urethral valves using a recursive feature elimination machine learning framework
Posterior urethral valves are a birth defect that blocks urine flow in boys and can damage the kidneys over time. Researchers built a computer model that picks out which patient measurements best predict how these boys will do. The model was trained on records of past patients, so it shows patterns linked to outcomes, not causes. It has not been tested on new patients in a trial.
Structured medication review in elderly patients with chronic kidney disease to assess treatment appropriateness
Clinicians went through the full medicine list of older adults with chronic kidney disease to check whether each drug was still the right choice. Older kidney patients often take many drugs, and some need a lower dose or should be stopped once the kidneys weaken. Work like this shows a link between reviews and better prescribing, not proof that the reviews make people live longer. No abstract was posted, so the number of patients and the size of any effect are not available.
Association of the Triglyceride–Glucose Index with Contrast-Associated Acute Kidney Injury in Patients with Atherosclerotic Renal Artery Stenosis
Researchers checked whether a simple score built from blood fat and blood sugar levels predicted kidney damage after patients received dye for an imaging scan. Everyone in the study had narrowed arteries feeding the kidneys, which already puts them at higher risk from the dye. This kind of study shows a link between a high score and kidney injury, not proof that the score's causes are what harm the kidney. No abstract was posted, so the number of patients and the strength of the link are not available.
Blood cadmium and mortality among U.S. stroke survivors: a survey-weighted NHANES-linked cohort study of competing risks and renal pathways
This study looked at cadmium levels in the blood of U.S. stroke survivors and whether higher levels went with a higher risk of dying. Cadmium is a toxic metal that people take in mostly from cigarette smoke and some foods, and the kidneys hold onto it. The researchers also tested whether kidney damage sits on the path between the metal and the deaths. It follows people over time without assigning anything, so it shows a link, not proof of cause, and it is a preprint that has not been peer reviewed.
The burden of bladder cancer and kidney cancer attributable to smoking in Latin America and the Caribbean from 1990 to 2023 and projections to 2050
This study counts how many bladder and kidney cancers in Latin America and the Caribbean can be traced to smoking, from 1990 through 2023, and projects the numbers out to 2050. It works from national population statistics rather than following individual patients, so it maps patterns instead of proving cause in any one person. Smoking is already an accepted cause of kidney cancer, and this puts a number on the regional burden. It is about cancer, not the gradual loss of kidney function.
Deciphering Geoenvironmental Determinants of Chronic Kidney Disease of Unknown Etiology: An Integrated Trace-Metal, Hydrological and Explainable Machine-Learning Framework for the Sri Lankan Dry Zone
In Sri Lanka's dry zone, many farm workers get kidney disease with no known cause. Researchers combined water data, trace metal levels, and machine learning to find which environmental features line up with where the disease clusters. This shows a link between local water and soil conditions and disease patterns, not proof that any one metal causes it. It is a preprint and has not passed peer review.
Obesity and reduced renal corticomedullary differentiation on T1 mapping: a population-based UK Biobank study
Researchers used MRI scans of the kidneys in UK Biobank, a very large group of British adults. People carrying more body fat had a blurrier line between the outer and inner parts of the kidney, which can be an early sign of kidney damage. This shows a link between weight and kidney appearance, not proof that weight caused it. The record we received did not include the number of people scanned.
Nutritional rehabilitation of elderly and senile patients with non-dialysis chronic kidney disease. Case report
Doctors describe a nutrition plan for one older adult who had chronic kidney disease but was not yet on dialysis. Poor nutrition and muscle loss are common at this stage and make people weaker and more fragile. This is a single patient story, so it can suggest a link but cannot prove the diet caused the change. No abstract was posted, so the weight, kidney numbers and follow-up time are not available.
Development and evaluation of an AI-based prediction model for chronic kidney disease after cardiac surgery.
Researchers built a computer tool that flags patients likely to develop chronic kidney disease after heart surgery, which often goes unnoticed for years. They used more than 200 pieces of routine medical information from heart surgery patients at a Danish hospital, then tested the tool on a separate group. The tool is designed to explain which factors drove each prediction. This is based on past medical records, so it shows patterns and risk, not proof of cause, and it has not been shown to improve outcomes.